Cerevel Therapeutics Holdings, Inc.
CERE · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$432,842 | -$351,511 | -$225,334 | -$152,142 |
| Dep. & Amort. | $5,627 | $4,903 | $2,731 | $397 |
| Deferred Tax | -$2,038 | $0 | $3,881 | $3,270 |
| Stock-Based Comp. | $69,410 | $38,780 | $23,941 | $10,521 |
| Change in WC | $16,113 | $28,064 | $15,541 | $17,707 |
| Other Non-Cash | $1,429 | -$13,423 | $694 | $2,445 |
| Operating Cash Flow | -$342,301 | -$293,187 | -$178,546 | -$117,802 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$3,808 | -$3,954 | -$10,503 | -$18,892 |
| Net Acquisitions | -$78 | $385 | $0 | $0 |
| Inv. Purchases | -$865,270 | -$887,737 | -$425,158 | $0 |
| Inv. Sales/Matur. | $942,800 | $502,857 | $0 | $0 |
| Other Inv. Act. | $78 | -$385 | -$425 | $0 |
| Investing Cash Flow | $73,722 | -$388,834 | -$435,661 | -$18,892 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $517,505 | $251,315 | $328,251 | $5,530 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $548,616 | $623,191 | $423,602 | $440,835 |
| Financing Cash Flow | $548,616 | $623,191 | $423,602 | $440,835 |
| Forex Effect | $548,755 | $0 | $0 | $0 |
| Net Chg. in Cash | $98,935 | -$58,830 | -$190,605 | $304,141 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $892,030 | $197,218 | $387,823 | $83,682 |
| End Cash | $990,965 | $138,388 | $197,218 | $387,823 |
| Free Cash Flow | -$346,109 | -$297,141 | -$189,049 | -$136,694 |